Cell-based chimeric antigen receptor (CAR) T cell therapies have rapidly advanced from preclinical research. This success has driven an influx of companies to further develop CAR T cell constructs to make them more effective, safe and persistent. On the manufacturing side, however, errors, lot-to-lot variation and contamination can be associated with open processing and manual handling of CAR T products. Overcoming the bioprocessing bottleneck remains a critical challenge in CAR T cell therapy scalability, which can potentially hinder both product development and patient access.
Download this whitepaper to discover a method that is:
- Consistently generating a pure and safe product
- GMP compliant